SODIOFOLIN

This brand name is authorized in United Kingdom

Active ingredients

The drug SODIOFOLIN contains one active pharmaceutical ingredient (API):

1 Sodium folinate
UNII Q573I9DVLP - LEUCOVORIN

Sodium folinate is a reduced derivative of folic acid. Sodium folinate is mainly used for colorectal cancer treatment in association with 5-fluorouracil and Oxaliplatin (FOLFOX regimen) or with 5-fluorouracil and Irinotecan (FOLFIRI regimen). Additionally, it is administered as salvage therapy to reduce toxic effects following high doses of methotrexate in the treatment of some neoplastic diseases, rheumatoid arthritis or severe psoriasis. Sodium folinate is also given to treat anemia caused by folate deficiency.

Read about Sodium folinate

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
SODIOFOLIN Solution for injection/infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
V03AF06 Sodium folinate V Various → V03 All other therapeutic products → V03A All other therapeutic products → V03AF Detoxifying agents for antineoplastic treatment
Discover more medicines within V03AF06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 47998, 48001

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.